Аналитика Telegram-канала
Подписчики
2 936
Охват за 24 ч
93
ER за 24 ч
3,17%
Публикаций
10 184

Динамика подписчиков

7 дней 30 дней 6 месяцев Больше
11 ноя14 ноя17 ноя
Показаны последние 7 дней Больше истории →

Охваты публикаций

16.1117.1117.1117.1117.1117.11
18
Средний охват
30
Лучший результат
Показаны 6 публикаций — последние в канале Больше статистики →

Упоминания

42
Упоминаний
16
Из них репостов
8
Каналов
Все упоминания

Последние посты

3 из 10 184 2 из 10 184
Breast Oncology ​🎗️ FDA APPROVAL | Breast Oncology FDA Approves Oral SERD Giredestrant (Wilserdly) Plus Everolimus for ESR1-Mutated Advanced Breast Cancer ​🔹 The Update: On November 16, the FDA approved the oral selective estrogen receptor degrader (SERD) Giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following progression on prior endocrine therapy, alongside the FoundationOne Liquid CDx companion diagnostic. In the Phase III evERA trial, the all-oral regimen reduced the risk of progression or death by 62% and nearly doubled median PFS (10.0 months vs. 5.5 months; HR 0.38, P less than 0.0001). ​🎯 Bedside Takeaway: Combining an oral SERD with mTOR inhibition overcomes co-occurring ESR1 and PI3K/AKT/mTOR resistance pathways in post-CDK4/6 inhibitor metastatic breast cancer, offering a potent all-oral alternative to fulvestrant-based combinations. ​🩺 @••• | Global Medical Updates #Oncology #BreastCancer #FDAApproval #Giredestrant #ESR1 #TheMDBriefing
ещё
15 0 17 ноя, 10:01
Neurogenetics & Rare Pediatric Endocrinology ​🧬 FDA REGULATORY UPDATE | Neurogenetics & Pediatric Endocrinology FDA Lifts Clinical Hold on Oral TAS2R Agonist ARD-101 for Prader-Willi Syndrome Hyperphagia ​🔹 The Update: The FDA lifted the clinical hold on ARD-101, an oral gut-restricted bitter taste receptor (TAS2R) agonist that stimulates endogenous cholecystokinin (CCK) and GLP-1 secretion via gut-brain vagal signaling, clearing the program to advance toward pivotal testing for hyperphagia in Prader-Willi Syndrome (PWS). ​🎯 Bedside Takeaway: Minimally absorbed oral TAS2R agonists offer a novel gut-brain satiety mechanism for neurogenetic hyperphagia; upcoming trial protocols will incorporate strict CYP2D6 substrate co-medication screening (such as pitolisant) to prevent drug-drug interactions. ​🩺 @••• | Global Medical Updates #MedicalGenetics #PediatricEndocrinology #RareDiseases #PraderWilliSyndrome #FDA #TheMDBriefing
ещё
21 0 17 ноя, 06:02
Adult Neuro-Oncology (SNO 2026) ​🎗️ CLINICAL COHORT | Neuro-Oncology (SNO 2026) Vorasidenib Shows Activity in Grade 3 IDH-Mutant Glioma & Sustains Long-Term Seizure Reduction ​🔹 The Update: New clinical analyses presented at SNO 2026 evaluating the dual IDH1/2 inhibitor Vorasidenib (Voranigo) across an 80-patient cohort of Grade 3 IDH-mutant diffuse gliomas demonstrated encouraging disease control beyond its classic Grade 2 indication, alongside extended longitudinal data confirming sustained reductions in tumor-associated seizure frequency and preserved health-related quality of life. ​🎯 Bedside Takeaway: By suppressing the oncometabolite 2-hydroxyglutarate (2-HG), vorasidenib directly reduces epileptogenic neuronal hyperexcitability in IDH-mutant gliomas while showing emerging therapeutic utility in selected Grade 3 tumors; monitor hepatic transaminases routinely. ​🩺 @••• | Global Medical Updates #NeuroOncology #Neurology #Glioma #Vorasidenib #SNO2026 #TheMDBriefing
ещё
17 0 17 ноя, 04:04
Больше постов

Продолжить анализ этого канала

  • История роста подписчиков
  • Просмотры и охваты публикаций
  • Кто упоминает канал и кого упоминает он
  • Похожие каналы и подбор для рекламы
Открыть аналитику
Демо до 14 дней